RETRACTED ARTICLE: Dysregulation of cell cycle related genes and microRNAs distinguish the low- from high-risk of prostate cancer by Jiling Wen et al.
RESEARCH Open Access
Dysregulation of cell cycle related genes and
microRNAs distinguish the low- from high-risk of
prostate cancer
Jiling Wen†, Rongbing Li†, Xiaofei Wen*, Guangming Chou, Jiasun Lu, Xuelei Wang and Yongchao Jin
Abstract
Background: Prostate cancer (PCa) is a biologically heterogeneous disease with considerable variation in clinical
aggressiveness. In this study, bioinformatics was used to detect the patterns of gene expression alterations of PCa
patients.
Methods: The gene expression profile GSE21034 and GSE21036 were downloaded from Gene Expression Omnibus
(GEO) database. Significantly changed mRNA transcripts and microRNAs were identified between subtypes with
favorable (cluster 2) and unfavorable (cluster 5) prognosis by two-side unequal variances t test. MicroRNAs and their
potential target genes were identified by TargetScan and miRTarBase, respectively. Besides, the overlapped genes
between the target genes of microRNAs and mRNA transcripts were assessed by Fisher’ exact test (one side). The
functional annotation was performed by DAVID, followed by construction of protein-protein interaction (PPI)
network.
Results: Compared to cluster 2, 1556 up-regulated and 1288 down-regulated transcripts were identified in cluster 5.
Total 28 microRNAs were up-regulated and 30 microRNAs were down-regulated in cluster 5. Besides, 12 microRNAs
target transcripts were significantly overlapped with down-regulated transcripts in cluster 5 with none of them
was found overlapped with up-regulated transcripts. Functional annotation showed that cell cycle was the most
significant function. In the PPI network, BRCA1, CDK1, TK1 and TRAF2 were hub protein of signature genes in cluster
5, and TGFBR1, SMAD2 and SMAD4 were hub proteins of signature gnens in cluster 2.
Conclusions: Our findings raise the possibility that genes related with cell cycle and dysregulated miRNA at
diagnosis might have clinical utility in distinguishing low- from high-risk PCa patients.
Virtual slides: The virtual slide(s) for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/
vs/13000_2014_156
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Background
Prostate cancer (PCa) is a highly prevalent disease in
older men of the western world [1]. In the US, total
241,740 men were diagnosed as PCa and 28,170 of them
died for the year 2012 [2]. Although the age-adjusted
rate of cancer deaths has decreased steadily in the past
10 years, PCa remains the second leading cause of can-
cer deaths in men after lung cancer [3]. The morbidity
and mortality of PCa is mainly caused by its propensity
to metastasize to other organs and tissues, such as lung,
liver and bone [4,5].
The clinical heterogeneity of PCa, coupled with its
high prevalence, raises challenges in the management of
newly diagnosed patients as well as those with metastatic
disease. Genomic-based classification offers the hope of
more informed clinical decision-making and may yield
novel therapeutic targets. To date, several potential bio-
markers including prostate cancer gene 3, methylation,
human kallikrein 2, prostate-specific membrane antigen
have been identified for the detection of PCa through
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molecular, biological, and genetic studies, but their pre-
dictive value remains to be conclusively verified [6-9].
Taylor et al. [10] reported the concordant assessment of
DNA copy number, mRNA and microRNAs expression,
and focused exon resequencing in prostate tumors. The
copy number alteration (CNA) analysis in that study re-
vealed two notable subgroups of primary tumors: those
with minimal CNA (clusters 1–4) and those with substan-
tial CNA (clusters 5–6) that include most of the metastatic
samples. Cluster 5 and 6 are distinguished by the fact that
cluster 5 tumors have genome-wide alterations, whereas
those in cluster 6 primarily have 8q (NCOA2, MYC) or
chromosome 7 gains. Among the tumors with minimal
CNA, cluster 2 is characterized by largely unaltered ge-
nomes. Using the endpoint of time to biochemical relapse,
primary tumors with generally diploid tumors in the min-
imally altered cluster 2 had an extremely favorable prog-
nosis versus an extremely unfavorable prognosis for the
highly altered cluster 5 tumors. However, the detailed gen-
omic differences between cluster 2 with favorable progno-
sis and cluster 5 with extremely unfavorable prognosis are
remaining unclear.
To reveal the potential genes and microRNAs which
might have clinical utility in distinguishing low- from
high-risk disease, we investigated the gene and micro-
RNAs expression profile between cluster 2 and cluster 5
PCa patients in the present study.
Methods
Microarray datasets
Normalized mRNA and microRNAs expression profile
data (GSE21034 and GSE21036) were downloaded from
Gene Expression Omnibus (GEO). Only mRNA tran-
scripts with Reference Sequence (Refseq) identifiers pre-
fixed with “NM_” were retained. MicroRNAs profiling
data were available for 8 (classified as cluster 5) and 25
PCa patients (classified as cluster 2), while mRNA profil-
ing data were available for 13 (classified as cluster 5) and
34 PCa patients (classified as cluster 2). The ethical com-
mittee of Memorial Sloan-Kettering Cancer Center Insti-
tutional Review Board approved the study protocol and
informed consent was obtained from all the patients.
Identification of differentially expressed mRNA transcripts
and microRNAs
Two-side unequal variances t test was used to identify
the differentially expressed mRNA transcripts between
cluster 2 and cluster 5. q value [11] is a well suited
measure of significance for genomewide tests with an
extension of a quantity called the “false discovery rate”
(FDR). q value < 0.05 was selected as cutoff. Significantly
changed mRNA transcripts were submitted to the online
tool Database for Annotation, Visualization, and Inte-
grated Discovery (DAVID) for functional annotation and
molecular signatures database (MSigDB) for finding out
potential links with published gene expression signature.
For microRNAs analysis, two-side unequal variance t test
was performed with the threshold of P < 0.05.
Identification of microRNA and their potential target gene
TargetScan [12] can predict biological targets of miRNAs
by searching for the presence of conserved 8mer and
7mer sites that match the seed region of each miRNA.
The miRTarBase [13] is a database which contains ex-
perimentally validated microRNA-target interactions.
Target genes were downloaded from TargetScan 6.2 and
experimentally validated target genes from miRTarBase
(version 3.5). Fisher’ exact test [14] (one side) was used
to assess the statistical significance of the overlapped
genes between the target genes of microRNAs and
mRNA transcripts.
Construction of protein-protein interaction (PPI) network
Most proteins perform their functions through interac-
tions and high-quality interaction networks can provide
key insights into fundamental topological and biological
properties of cellular systems. Thus, the PPI data were
downloaded from HINT [15] database for construction of
PPI network of significantly changed signature genes.
Refseq mRNA identifiers were mapped to EntrezGene
identifiers and extracted the interactions between signifi-
cantly changed signature genes. Proteins with at least ten
interactions were considered as hubs in the present study.
Results
Identification of significantly altered transcripts between
cluster 2 and cluster 5
Compared with cluster 2, 1556 transcripts were found
up-regulated and 1288 transcripts were down-regulated
in cluster 5. Functional annotation analysis revealed that
Cluster 5 signature genes were mainly enriched in the
cell cycle and proliferation pathways, while cluster 2 sig-
nature genes were enriched in the pathways of response
to stimulus, like steroid hormone. MSigDB investigation
showed that these PCa subtype signature was correlated
with many published gene signature. The most interest-
ing finding was that the down-regulated genes in PC3
cell after knockdown of EZH2 by RNAi were signifi-
cantly overlapped with the cluster 5 gene signature, and
up-regulated genes were significantly overlapped with
the cluster 2 gene signature. Compared to cluster 2, two
mRNA transcripts (NM_004456, NM_152998) of EZH2
were significantly up-regulated in cluster 5.
Identification of dysregulated microRNAs and their potential
target gene
Compared with cluster 2, 28 microRNAs were up-regulated
and 30 microRNAs were down-regulated in cluster 5
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Table 1 MicroRNAs that significantly changed in cluster 2 and 5
MicroRNAs Fold-change P-value Chromosome region
Up-regulated
hsa-miR-151-3p 1.08 2.5 E-2 8
hsa-miR-1237 1.33 8.8 E-3 11
hsa-miR-548c-3p 1.63 2.6 E-2 12
hsa-miR-1228 1.14 1.8 E-2 12
hsa-miR-130b 1.13 9.2 E-3 22
hsa-miR-210 1.17 3.5 E-2 11p15.5
hsa-miR-141 1.07 1.18 E-2 12p13.31
hsa-miR-19b-1* 1.30 4.06 E-2 13q31.3
hsa-miR-627 1.23 2.65 E-2 15q15.1
hsa-miR-1225-3p 1.15 4.85 E-2 16p13.3
hsa-miR-33b 2.10 4.08 E-3 17p11.2
hsa-miR-423-3p 1.22 2.15 E-2 17q11.2
hsa-miR-423-5p 1.09 2.26 E-2 17q11.2
hsa-miR-636 1.21 1.38 E-2 17q25.1
hsa-let-7a* 1.50 9.55 E-3 22q13.31
hsa-miR-191* 1.33 3.78 E-4 3p21.31
hsa-miR-425* 1.26 6.50 E-3 3p21.31
hsa-miR-16-2* 1.18 3.39 E-2 3q25.33
hsa-miR-148a* 1.26 2.59 E-2 7p15.2
hsa-miR-93 1.08 2.32 E-2 7q22.1
hsa-miR-106b 1.06 4.87 E-2 7q22.1
hsa-miR-335* 1.39 3.20 E-2 7q32.2
hsa-miR-182 1.20 8.72 E-3 7q32.2
hsa-miR-30d* 1.27 2.81 E-2 8q24.22
hsa-miR-30d 1.07 1.99 E-2 8q24.22
hsa-miR-491-5p 1.45 2.64 E-2 9p21.3
hsa-miR-602 1.24 1.13 E-2 9q34.3
hsa-miR-542-5p 1.20 2.15 E-2 Xq26.3
Down-regulated
hsa-miR-130a 0.87 2.70 E-2 11q12.1
hsa-miR-100 0.85 2.40 E-2 11q24.1
hsa-miR-125b 0.90 3.80 E-2 11q24.1,21q21.1
hsa-miR-136* 0.85 2.90 E-2 14q32.2
hsa-miR-495 0.82 4.48 E-2 14q32.31
hsa-miR-132 0.88 1.03 E-2 17p13.3
hsa-miR-132* 0.89 1.70 E-2 17p13.3
hsa-miR-152 0.89 3.24 E-2 17q21.32
hsa-miR-338-3p 0.82 5.61 E-4 17q25.3
hsa-miR-133a 0.71 3.41 E-3 18q11.2,20q13.33
hsa-miR-30e* 0.89 3.59 E-2 1p34.2
hsa-miR-30c 0.90 2.41 E-2 1p34.2,6q13
hsa-miR-205 0.63 4.50 E-2 1q32.2
hsa-miR-499-5p 0.83 2.61 E-2 20q11.22
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(Table 1). Besides, 12 microRNAs target transcripts were
significantly overlapped with down-regulated transcripts in
cluster 5. However, no microRNA target transcript was
found overlapped with up-regulated transcripts in cluster 5
(Table 2).
PPI network analysis
The results of PPI network analysis showed that there were
46 nodes and 46 edges in cluster 5 (Figure 1). Meanwhile,
total 27 nodes and 34 edges were in cluster 2 (Figure 2).
Proteins with at least ten interactions were considered as
hubs. The results revealed that BRCA1, CDK1, TK1 and
TRAF2 were hub protein of signature genes in cluster 5,
and TGFBR1, SMAD2 and SMAD4 were hub proteins of
signature gnens in cluster 2.
Discussion
The clinical heterogeneity of PCa, coupled with its high
prevalence, raises challenges in the management of
newly diagnosed patients as well as those with metastatic
disease. Genomic-based classification offers the hope of
more informed clinical decision and may yield novel
therapeutic targets. In this bio-information analysis, we
found that cell cycle was selected as the most significant
pathway. The androgen receptors (AR) related genes,
such as CDK1 and BRCA1 might play important roles in
the development of PCa.
Transcriptions in cluster 5 were associated with
EZH2-mediated regulation
EZH2 encodes a member of the Polycomb-group (PcG)
family which involved in maintaining the transcriptional
repressive state of genes over successive cell generations.
Xu K et al. [16] have found that the oncogenic function
of EZH2 in cells of castration-resistant PCa is independ-
ent of its role as a transcriptional repressor. Instead, it
involves the ability of EZH2 to act as a coactivator for
critical transcription factors including AR. Phosphoryl-
ation of EZH2 and an intact methyltransferase domain
were required for this functional switch. In the present
Table 1 MicroRNAs that significantly changed in cluster 2 and 5 (Continued)
hsa-miR-1 0.69 3.76 E-3 20q13.33
hsa-miR-218 0.83 1.79 E-2 4p15.31,5q34
hsa-miR-145* 0.74 1.01 E-2 5q32
hsa-miR-143 0.78 1.64 E-2 5q32
hsa-miR-143* 0.80 1.24 E-2 5q32
hsa-miR-145 0.86 2.43 E-2 5q32
hsa-miR-378* 0.93 2.50 E-2 5q32
hsa-miR-133b 0.77 6.36 E-3 6p12.2
hsa-miR-204 0.72 1.79 E-2 9q21.12
hsa-miR-24-1* 0.79 7.48 E-3 9q22.32
hsa-miR-27b 0.88 1.29 E-2 9q22.32
hsa-miR-23b 0.88 2.56 E-2 9q22.32
hsa-miR-455-5p 0.76 5.74 E-3 9q32
hsa-miR-455-3p 0.80 2.85 E-2 9q32
hsa-miR-221* 0.67 670 E-4 Xp11.3
hsa-miR-221 0.80 4.19 E-3 Xp11.3
hsa-miR-223 0.90 2.59 E-2 Xq12
“*” stands for the miRNA which is expressed at low levels.
Table 2 TargetScan target transcripts of microRNAs that
up-regulated in cluster 5 significantly overlapped with
mRNA transcripts that down-regulated in cluster 5
compared to cluster 2
Number of targets Number of
overlapped targets
p-value
hsa-miR-548c-3p 2611 288 3.62E-38
hsa-miR-30d 1773 195 4.37E-25
hsa-miR-130b 1205 151 5.33E-25
hsa-miR-93 1583 153 1.18E-14
hsa-miR-106b 1583 153 1.18E-14
hsa-miR-33b 544 69 3.44E-12
hsa-miR-141 996 102 1.66E-11
hsa-miR-636 874 92 3.97E-11
hsa-miR-182 1494 131 8.35E-10
hsa-miR-1228 274 34 1.74E-06
hsa-miR-602 33 7 1.19 E-3
hsa-miR-151-3p 145 16 3.12 E-3
Note: Fisher’s exact test was applied to assess the statistical significance and
only those with p-value < 0.005 were shown.
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study the transcriptions in cluster 5 were overlapped
with those down-regulated genes after knockdown of
EZH2. Indeed, two mRNA transcripts (NM_004456,
NM_152998) of EZH2 were significantly up-regulated
in cluster 5 PCa compared to cluster 2. Our finding of
PCa subtype gene signature was associated with EZH2-
mediated regulation which further addressed the import-
ant role of EZH2 in the progress of PCa.
The up-regulated genes which were related to cell cycle
in cluster 5 might have prognostic value
Functional annotation in the present study showed
that Cluster 5 up-regulated signature genes were mainly
associated with cell cycle. Proper regulation of the cell
division cycle is crucial to the growth and development
of all organisms. Actually, some cell cycle progression
(CCP) genes have been identified as having RNA expres-
sion levels that oscillated as cells progressed through
various stages of the cell cycle [17]. Cell cycle-regulated
transcripts of genes involved in fundamental processes
such as DNA replication and chromosome segregation
seem to be more highly expressed in proliferative tumors
simply because they contain more cycling cells. Mandal
et al. [18] suggested that there was a positive association
of cyclin D1AA genotype and diplotype analysis of Fas
G670A and G1377A (G-A) which was associated with
CaP risk by influencing the pathophysiology of CaP.
Cuzick et al. [19] found that the cell cycle progression
signature was a highly significant predictor of outcome
in both cohorts of PCa patients. Since the expression
levels of CCP genes probably reflect fundamental aspects
of tumour biology, we reasoned that the up-regulated
genes related with cell cycle in the present study might
also be useful in PCa.
MicroRNAs could play regulatory roles of PCa subtype
gene signature
In the present study, miR-1 was found significantly up-
regulated in cluster 5 PCa. Kojima et al. found that the
expression levels of miR-1 and miR-133a were signifi-
cantly down-regulated in PCa compared with non-PCa
tissues [20]. Restoration of miR-1 or miR-133a in PC3
and DU145 cells revealed significant inhibition of prolif-
eration, migration, and invasion. They further suggest
that miR-1 and miR-133 could be tumor suppressors by
targeting purine nucleoside phosphorylase (PNP). Other
Figure 1 Protein-protein interactions in cluster 5 signature genes. Yellow nodes are those interacted with androgen receptor. Protein-protein
interactions were downloaded from database HINT which removes low-quality/erroneous interactions by both systematically and manually filtering.
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microRNAs also has close relationship with PCa, for ex-
ample, loss of microRNA-126 has been reported to play
a positive role in the progression of PCa [21]. Mean-
while, we also found that predicted targets of other up-
regulated microRNAs could significantly overlap with
down-regulated genes in cluster 5 PCa. The roles of
these microRNAs in PCa might worth further investigat-
ing according to the previous studies [22-24].
BRCA1 and CDK1, both interacted with AR were hub
proteins of cluster 5
Genetic factor has been considered to be critical in the de-
velopment and progression of PCa. Aldo-keto reductase
family 1 member C3 (AKR1C3) has been found to serve
as a hopeful biomarker and is closely related to the pro-
gression of PCa [25]. In the present study, we found
BRCA1 and CDK1 were strong related to PCa. The ex-
pression of AR is maintained throughout PCa progression,
and the majority of androgen-independent or hormone
refractory PCa express AR. Similarly, alterations in the
relative expression of AR coregulators have been found to
occur with PCa progression and may contribute to differ-
ences in AR ligand specificity or transcriptional activity
[26]. Inhibiting AR signaling remains one of the most
common and effective systemic methods to treat PCa.
BRCA1 might function as an AR coregulator and directly
modulate AR signaling [27]. Yeh S et al. report that
BRCA1 interacts with androgen receptor and enhances
AR target genes, such as p21 (WAF1/CIP1) that may re-
sult in the increase of androgen-induced cell death in
PCa cells [28]. Another hub protein CDK1 was also found
to be significantly expressed in “androgen-independent”
PCa which relapse subsequent to androgen-deprivation
therapy. It was suggested that AR is active and seems to
be stabilized by low level of androgen in such PCa and
treatment with roscovitine, a Cdk inhibitor, could abrogate
responses to low levels of androgen in the androgen-
independent PCa cell line [29].
Our analysis also addresses the important role of
TGF-beta signaling in cluster 2 PCa. Combined with
Figure 2 Protein-protein interactions in cluster 2 signature genes. Protein-protein interactions were downloaded from database HINT which
removes low-quality/erroneous interactions by both systematically and manually filtering.
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our finding, investigation of the roles of TGFBR1 and
SMAD4 in PCa could be of great value. However, there
were still some limitations in this study. A further inves-
tigation in cluster 2 and 5 related to PCa is needed.
Conclusion
In summary, our findings raise the possibility that genes
related with cell cycle and dysregulated miRNA at diag-
nosis might have clinical utility in distinguishing low-
from high-risk PCa patients. However, as our results
were based on microarray data derived from a small
sample size, further experimental validation is needed.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
Design the experiments: XW, JW; Analyze and interpret of data: JW, RL, GC,
JL; Draft the article: XW, YJ, XW. All authors read and approved the final
manuscript.
Acknowledgements
We thank Fudan University, college of life science.
Received: 14 April 2014 Accepted: 29 July 2014
References
1. Chan JM, Jou RM, Carroll PR: The relative impact and future burden of
prostate cancer in the United States. J Urol 2004, 172:S13–S16. discussion S17.
2. Siegel R, Naishadham D, Jemal A: Cancer statistics, 2012. CA Cancer J Clin
2012, 62:10–29.
3. Shen MM, Abate-Shen C: Molecular genetics of prostate cancer: new
prospects for old challenges. Genes Dev 2010, 24:1967–2000.
4. Berezikov E, Guryev V, Van De Belt J, Wienholds E, Plasterk RH, Cuppen E:
Phylogenetic shadowing and computational identification of human
microRNA genes. Cell 2005, 120:21–24.
5. Logothetis CJ, Lin SH: Osteoblasts in prostate cancer metastasis to bone.
Nat Rev Cancer 2005, 5:21–28.
6. Nogueira L, Corradi R, Eastham JA: Other biomarkers for detecting
prostate cancer. BJU Int 2010, 105:166–169.
7. Hoque MO, Kim MS, Ostrow KL, Liu J, Wisman GB, Park HL, Poeta ML,
Jeronimo C, Henrique R, Lendvai A, Schuuring E, Begum S, Rosenbaum E,
Ongenaert M, Yamashita K, Califano J, Westra W, Van Der Zee AG, Van
Criekinge W, Sidransky D: Genome-wide promoter analysis uncovers
portions of the cancer methylome. Cancer Res 2008, 68:2661–2670.
8. Schilling D, De Reijke T, Tombal B, De La Taille A, Hennenlotter J, Stenzl A:
The Prostate Cancer gene 3 assay: indications for use in clinical practice.
BJU Int 2010, 105:452–455.
9. Hoque MO: DNA methylation changes in prostate cancer: current
developments and future clinical implementation. Expert Rev Mol Diagn
2009, 9:243–257.
10. Taylor BS, Schultz N, Hieronymus H, Gopalan A, Xiao Y, Carver BS, Arora VK,
Kaushik P, Cerami E, Reva B, Antipin Y, Mitsiades N, Landers T, Dolgalev I,
Major JE, Wilson M, Socci ND, Lash AE, Heguy A, Eastham JA, Scher HI,
Reuter VE, Scardino PT, Sander C, Sawyers CL, Gerald WL: Integrative
genomic profiling of human prostate cancer. Cancer Cell 2010, 18:11–22.
11. Storey JD, Tibshirani R: Statistical significance for genomewide studies.
Proc Natl Acad Sci U S A 2003, 100:9440–9445.
12. Friedman RC, Farh KK, Burge CB, Bartel DP: Most mammalian mRNAs are
conserved targets of microRNAs. Genome Res 2009, 19:92–105.
13. Hsu SD, Lin FM, Wu WY, Liang C, Huang WC, Chan WL, Tsai WT, Chen GZ,
Lee CJ, Chiu CM, Chien CH, Wu MC, Huang CY, Tsou AP, Huang HD:
miRTarBase: a database curates experimentally validated microRNA-target
interactions. Nucleic Acids Res 2011, 39:D163–D169.
14. Daya S: Fisher exact test. Evid Based Obstet Gynecol 2002, 4:3–4.
15. Das J, Yu H: HINT: high-quality protein interactomes and their applications
in understanding human disease. BMC Syst Biol 2012, 6:92.
16. Xu K, Wu ZJ, Groner AC, He HH, Cai C, Lis RT, Wu X, Stack EC, Loda M, Liu T,
Xu H, Cato L, Thornton JE, Gregory RI, Morrissey C, Vessella RL, Montironi R,
Magi-Galluzzi C, Kantoff PW, Balk SP, Liu XS, Brown M: EZH2 oncogenic
activity in castration-resistant prostate cancer cells is Polycomb-independent.
Science 2012, 338:1465–1469.
17. Whitfield ML, Sherlock G, Saldanha AJ, Murray JI, Ball CA, Alexander KE,
Matese JC, Perou CM, Hurt MM, Brown PO, Botstein D: Identification of
genes periodically expressed in the human cell cycle and their
expression in tumors. Mol Biol Cell 2002, 13:1977–2000.
18. Mandal RK, Mittal RD: Are cell cycle and apoptosis genes associated
with prostate cancer risk in North Indian population? Urol Oncol 2010,
30:555–561.
19. Cuzick J, Swanson GP, Fisher G, Brothman AR, Berney DM, Reid JE, Mesher
D, Speights VO, Stankiewicz E, Foster CS, Moller H, Scardino P, Warren JD,
Park J, Younus A, Flake DD II, Wagner S, Gutin A, Lanchbury JS, Stone S:
Prognostic value of an RNA expression signature derived from cell cycle
proliferation genes in patients with prostate cancer: a retrospective
study. Lancet Oncol 2011, 12:245–255.
20. Kojima S, Chiyomaru T, Kawakami K, Yoshino H, Enokida H, Nohata N,
Fuse M, Ichikawa T, Naya Y, Nakagawa M, Seki N: Tumour suppressors
miR-1 and miR-133a target the oncogenic function of purine nucleoside
phosphorylase (PNP) in prostate cancer. Br J Cancer 2012, 106:405–413.
21. Sun X, Liu Z, Yang Z, Xiao L, Wang F, He Y, Su P, Wang J, Jing B: Association of
microRNA-126 expression with clinicopathological features and the risk of
biochemical recurrence in prostate cancer patients undergoing radical
prostatectomy. Diagn Pathol 2013, 8:1746–1596.
22. Fang L, Deng Z, Shatseva T, Yang J, Peng C, Du WW, Yee AJ, Ang LC, He C,
Shan SW, Yang BB: MicroRNA miR-93 promotes tumor growth and
angiogenesis by targeting integrin-beta8. Oncogene 2011, 30:806–821.
23. Li Y, Tan W, Neo TW, Aung MO, Wasser S, Lim SG, Tan TM: Role of the
miR-106b-25 microRNA cluster in hepatocellular carcinoma. Cancer Sci
2009, 100:1234–1242.
24. Yang IP, Tsai HL, Hou MF, Chen KC, Tsai PC, Huang SW, Chou WW, Wang JY,
Juo SH: MicroRNA-93 inhibits tumor growth and early relapse of human
colorectal cancer by affecting genes involved in the cell cycle.
Carcinogenesis 2012, 33:1522–1530.
25. Tian Y, Zhao L, Zhang H, Liu X, Zhao X, Li Y, Li J: AKR1C3 overexpression
may serve as a promising biomarker for prostate cancer progression.
Diagn Pathol 2014, 9:1746–1596.
26. Heinlein CA, Chang C: Androgen receptor in prostate cancer. Endocr Rev
2004, 25:276–308.
27. Park JJ, Irvine RA, Buchanan G, Koh SS, Park JM, Tilley WD, Stallcup MR, Press
MF, Coetzee GA: Breast cancer susceptibility gene 1 (BRCAI) is a
coactivator of the androgen receptor. Cancer Res 2000, 60:5946–5949.
28. Yeh S, Hu YC, Rahman M, Lin HK, Hsu CL, Ting HJ, Kang HY, Chang C:
Increase of androgen-induced cell death and androgen receptor
transactivation by BRCA1 in prostate cancer cells. Proc Natl Acad Sci U S A
2000, 97:11256–11261.
29. Chen S, Xu Y, Yuan X, Bubley GJ, Balk SP: Androgen receptor phosphorylation
and stabilization in prostate cancer by cyclin-dependent kinase 1.
Proc Natl Acad Sci U S A 2006, 103:15969–15974.
doi:10.1186/s13000-014-0156-1
Cite this article as: Wen et al.: Dysregulation of cell cycle related genes
and microRNAs distinguish the low- from high-risk of prostate cancer.
Diagnostic Pathology 2014 9:156.
Wen et al. Diagnostic Pathology 2014, 9:156 Page 7 of 7
http://www.diagnosticpathology.org/content/9/1/156
